Bioeurope, 2018, 24th annual partnering conference,
Copenhagen November, 5-7, participation for a client to search investors
UEGW 2018, Vienna, October, 20-24, participation
SMI Drug Discovery Conference 2018,
London, March 21-22, Hanauer Guido chairman 2nd day
Safety Pharmacology Society 2017,
Berlin, September, 24-27, participation
SMI Drug Discovery Conference 2017,
London, March 27-28, Hanauer Guido keynote speaker: Is translational medicine capable to increase the success rate in the pharmaceutical industry
Oxford Global Drug Discovery Summit 2016,
Berlin, June 13-14, Hanauer Guido keynote speaker: The future of translational medicine
DDIP Drug Discovery Innovation Program 2016,
Hamburg, October 20-21, Hanauer Guido keynote speaker and chairman 2nd day: Dealing with discovery and optimization challenges for small molecule drug candidates.
DDIP Drug Discovery Innovation Program 2015,
Munich, November 25-26: Hanauer Guido keynote speaker: Translational Medicine bridging discovery and clinical development
Rabe KF, Saetta M, Watz H, Baraldo S, Hanauer G, Goehring UM, Roman J, Ala-gappan V: An exploratory 16-week, randomised, placebo-controlled, trial to assess the anti-inflammatory effects of roflumilast in COPD (ROBERT), 2018, Lancet Res-piratory: submitted
Rabe KF, Hanauer G, Strigun A, Alagappan V: Effects of Roflumilast on the serum metabolome of COPD patients. Poster ATS Meeting May 18-23, 2018 San Diego, USA
van Koppen A, Verschuren L, van den Hoek AM, Verheij J, Morrison MC, Li K, Na-gabukuro H, Costessi A, Caspers MPM, van den Broek TJ, Sagartz J, Kluft C, Bey-sen C, Emson C, van Gool AJ, Goldschmeding R, Stoop R, Bobeldijk-Pastorova I, Turner SM, Hanauer G, Hanemaaijer R: Uncovering a Predictive Molecular Signa-ture for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model Cell Mol Gastroenterol Hepatol. 2018; 5(1): 83–98.e10.
Plock N, Vollert S, Mayer M, Hanauer G, Lahu G: Pharmacokinet-ic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK-648 in Type 2 Diabetes using preclinical and first-in-human data – Value of Early Translational Approaches for Human Dose Prediction. Clinical and Translational Science, 2017 May;10(3):185-193. doi: 10.1111/cts.12436
Rabe KF, Saetta M, Watz H, Baraldo S, Hanauer G, Göhring UM, Delgadillo J, Román J, Alagappan V: Reduction in airway eosinophils in patients with COPD treated with roflumilast for 16 weeks: A double-blind, parallel-group, randomized, placebo-controlled biopsy trial. Poster ATS meeting May 19-24 2017, Washington D.C, late braking abstract 12764
Ookawara M, Nio Y, Yamasaki M, Kuniyeda K, Hanauer G, Hazama M, Matsuo T: Novel and selective Phosphodiesterase Type 4 Inhibitor Ameliorates Albuminuria in Mouse Model of Diabetic Nephropathy, Poster No. TH-PO-442, Kidney week, Ameri-can Society of Neurology, 2016.
Thur Y, Bhalerao A, Munshi Z, Pansare N, Mann K, Hanauer G, Kley HP, Nappe S, Weiss-Haljiti C, Ostermann C, Zitt C, Schaefer M, Mondal D, Ali Siddiki A, Armugam V, Gudaghe V, Gupta M, Rayudu P, Dautzenberg FM, Das Sarma K. (2012). Struc-ture-activity relationships of 2-arylamido-5,7-dihydro-4H-thieno[2,3-c]pyran-3-carboxamide derivatives as cannabinoid receptor agonists and their analgesic ac-tion. Bioorg Med Chem Lett. 2012 Dec 15;22(24):7314-21.
Vollert S, Kessner N, Heuser A, Hanauer G, Dieckmann A, Knaak D, Kley HP, Beu-me R, Weiss-Haljiti C (2012). The glucose lowering effects of the PDE4 inhibitors Roflumilast and his N-oxide in db/db mice. Diabetologica Oct 55 (10) 279-288